# HB0036

Source: https://onco.cc/drugs/hb0036/  
OnCo record `hb0036` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HB0036 is an experimental investigational agent whose form is not stated in the registry from Shanghai Huaota Biopharmaceutical in phase 2 trials for non-small-cell lung cancer, aimed at PD-L1 and TIGIT.

## Summary

HB0036 is an investigational agent whose form is not stated in the registry developed by Shanghai Huaota Biopharmaceutical. Its targets are PD-L1 and TIGIT (the sponsor names PD-L1 x TIGIT). The sponsor states: HB0036 is an anti-PD-L1/anti-TIGIT bifunctional antibody molecule, given by intravenous infusion every three weeks, simultaneously engaging both checkpoint pathways. ClinicalTrials.gov describes the intervention as: Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT05417321, plans to enrol 80 participants with primary completion was scheduled for 2025-08-01 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: Anti-PD-L1 and anti-TIGIT bifunctional molecule
- Tags: pipeline; ctgov-ingest
- Modality: bifunctional antibody (anti-PD-L1/anti-TIGIT, per the sponsor's description; form not stated in the registry record)
- Mechanism: HB0036 is an anti-PD-L1/anti-TIGIT bifunctional antibody molecule, given by intravenous infusion every three weeks, simultaneously engaging both checkpoint pathways.

## Sources

- ClinicalTrials.gov: trials of HB0036: https://clinicaltrials.gov/search?intr=HB0036

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/), [TIGIT](https://onco.cc/targets/tigit/)
- companies: [Huabo Biopharm](https://onco.cc/companies/huabo-biopharm/)
- trials: [A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct05417321/)

---
JSON: https://onco.cc/api/v1/entities/hb0036.json